CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
CervoMed (CRVO) had its price target lowered by Roth Mkm from $19.00 to $11.00. They now have a "buy" rating on the stock.
CervoMed (CRVO) had its price target raised by Chardan Capital from $15.00 to $21.00. They now have a "buy" rating on the stock.